12:00 AM
Nov 19, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

NBTXR3: Phase I ongoing

Nanobiotix said an IDMC recommended continuation of the open-label, dose-escalation, French Phase I trial of NBTXR3 after reviewing safety data from the first 6 patients treated. The trial is evaluating a single intratumoral injection of NBTXR3 prior...

Read the full 162 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >